About ANGLE plc
ANGLE plc is a company based in Surrey (Canada) founded in 1994. It operates as a HealthTech and Professional Services. The company has 119 employees. ANGLE plc offers products and services including Parsortix PC1 System, Parsortix PR1 System, Portrait+ CTC Staining Kit, and Laboratory Services. ANGLE plc operates in a competitive market with competitors including Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
- Headquarter Surrey, Canada
- Employees 119
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website angleplc.com
- Social LinkedIn X
- Legal Name Cellbxhealth Plc
- Annual Revenue$3.58 M (USD)30.92as on Dec 31, 2024
- Net Profit-$17.82 M (USD)29.34as on Dec 31, 2024
- EBITDA-$17.27 M (USD)24.1as on Dec 31, 2024
- Latest Funding Round$23.67M (USD), Post-IPO
Jul 2022
- Investors
- Employee Count119
Products & Services of ANGLE plc
ANGLE plc offers a comprehensive portfolio of products and services, including Parsortix PC1 System, Parsortix PR1 System, Portrait+ CTC Staining Kit, and Laboratory Services.
Automated system for capturing circulating tumor cells used.
Research system for circulating tumor cell harvesting provided.
Kit for staining circulating tumor cells in analysis.
Custom CTC analysis services for research are offered.
Funding Insights of ANGLE plc
- Total Rounds 6
- Last Round Post-IPO — $23.67M
- First Round $250,000
(Feb 2015)
- Investors Count 1
All 6 funding rounds of ANGLE plc with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2022 | $23.67M | Post-IPO | – | – | – |
| Oct 2020 | $25.92M | Post-IPO | – | – | – |
| Jun 2018 | $14.83M | Post-IPO | – | – | – |
| Jan 2018 | $557,523 | Grant | – | – | |
| Oct 2017 | $16.18M | Post-IPO | – | – | – |
| Feb 2015 | $250,000 | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in ANGLE plc
ANGLE plc has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for ANGLE plc
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ANGLE plc
37 people are tracked at ANGLE plc (11 in leadership, 11 in board & advisors, 15 in team); the tracked headcount is 119.
| Name | Role | Group |
|---|---|---|
Ghada Abuali | Business Solutions & Strategy Director | Leadership |
Ron Burton | Regional Business Director Angle Plc | Leadership |
Michelle Munson | HR Director | Leadership |
Ian Griffiths | Chief Financial Officer | Leadership |
Andrew Newland | Chief Executive | Leadership |
Karen Miller | Chief Scientific Officer | Leadership |
Brett Swansiger | Chief Commercial Officer | Leadership |
Craig Miller | Clinical Studies Director | Leadership |
Anne-Sophie Pailhes-Jimenez | R&D Director | Leadership |
Mariacristina Ciccioli | Head Of Assay Development | Leadership |
Dr. Alexandre Izmailov | VP Of Engineering | Leadership |
Ashok Venkitaraman | Scientific Advisor | Board & advisors |
James Reuben | Scientific Advisor | Board & advisors |
Jan Groen | Chairman | Board & advisors |
Brian Howlett | Non-executive Director & Senior Independent Director | Board & advisors |
Clive Stanway | Scientific Advisor | Board & advisors |
Joseph Khoury | Scientific Advisor | Board & advisors |
Adrian Newland | Scientific Advisor | Board & advisors |
Harold Swerdlow | Scientific Advisor | Board & advisors |
Greg Shaw | Scientific Advisor | Board & advisors |
17 more people are available in the full profile.
Complete people profiles for ANGLE plc
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of ANGLE plc
ANGLE plc is a publicly listed company on the LSE with ticker symbol AGL in UK, operating in the Distribution services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Mar 2004
- Listed onLSE: AGL
- Listed entityANGLE plc
- Exchange sectorDistribution services
- ISINGB0034330679
- Share price0.88 GBX (+3.53% on the day) · 2026-10-09
- Market capitalisation9,659,423.00 GBX
- EPS (diluted, trailing year)-0.03 GBX
- Volume (last session)25,479
Financials of ANGLE plc
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1.4M GBP | -19.5M GBP | -12.9M GBP |
| 2024 | 2.9M GBP | -14.2M GBP | -13.8M GBP |
| 2023 | 2.2M GBP | -20.1M GBP | -18.1M GBP |
| 2022 | 1.0M GBP | -21.7M GBP | -23.3M GBP |
| 2021 | 1.0M GBP | -15.0M GBP | -15.9M GBP |
Detailed financial statements for ANGLE plc
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of ANGLE plc
4 dated milestones of ANGLE plc across 28 years, from founding to its latest funding, stage changes and deals.
- Founded ANGLE plc is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $250K.
- Funding Latest funding round, Post-IPO, of $23.7M.
Competitors of ANGLE plc
ANGLE plc operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| prenetics.com | 2009 | Hong Kong, China | $67.65M | – | Health risks are identified through online genetic and diagnostic testing. | |
| thrivedetect.com | 2019 | Cambridge, United States | $367M | 138 | Blood-based liquid biopsy tests for multiple cancer detection are provided. | |
| veracyte.com | 2008 | San Francisco, United States | $67.9M | 815 | Genomics-based diagnostic tests for cancer are developed. | |
| delfidiagnostics.com | 2019 | Baltimore, United States | $331.59M | – | Provider of DNA sequencing for cancer detection |
Detailed competitors of ANGLE plc
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ANGLE plc
Websites that share an audience with ANGLE plc (angleplc.com).
Websites whose visitors overlap most with ANGLE plc. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
glucorx.co.uk | glucorx.co.uk | 100% | – | #1,229,062 | – |
nisra.org | nisra.org | 83% | – | #2,215,033 | – |
communere.com | communere.com | 43% | – | #13,699,672 | – |
Latest news on Angle Plc
Complete news archive for ANGLE plc
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ANGLE plc
10 companies that operate in the same segment as ANGLE plc (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ANGLE plc
ANGLE plc was founded in 1994 and raised its 1st funding round 21 years after it was founded.
ANGLE plc is headquartered in Surrey, Canada. It is registered at Surrey, British Columbia, Canada.
ANGLE plc has 119 employees.
Annual revenue of ANGLE plc is $3.58M as on Dec 31, 2024.
ANGLE plc is engaged in developing liquid biopsy solutions for cancer diagnosis, prognosis, and treatment. The company specializes in circulating tumor cell (CTC) harvesting through its proprietary Parsortix technology, which is utilized in clinical and research settings. Solutions are provided for various cancer types, including breast, prostate, ovarian, lung, and glioblastoma. Laboratory services are offered globally to support biopharmaceutical and translational research. The focus is placed on precision medicine by enabling downstream analysis of CTCs for personalized treatment approaches.
ANGLE plc's top competitors include Guardant Health, Foundation Medicine and Natera.
ANGLE plc offers Parsortix PC1 System, Parsortix PR1 System, Portrait+ CTC Staining Kit, and Laboratory Services.
Yes, ANGLE plc is publicly traded on LSE under the ticker symbol AGL.
ANGLE plc has 1 investor. Key investors include European Union.
ANGLE plc operates through Angle Plc.